Answers are grounded in this paper and cite their sources.
BACKGROUND: Children with uncontrolled, moderate-to-severe asthma often have type 2 disease with allergic sensitization and/or elevated serum IgE. OBJECTIVE: To examine dupilumab efficacy in children aged 6 to 11 years with/without allergen sensitization. METHODS: ), Interviewer-Administered 7-Item Asthma Control Questionnaire (ACQ-7-IA) score, and total and allergen-specific IgE levels. CONCLUSION: In children with type 2 asthma, dupilumab showed significant efficacy, reducing exacerbations and improving other outcomes in monoallergen- and multiallergen-sensitized patients, and numerical but nonsignificant effects in nonsensitized patients.
No takes yet. Share an insight, caveat, or question.
Phipatanakul et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: